Pertuzumab represents a new class of targeted anticancer agents, human epidermal growth factor receptor (HER) dimerization inhibitors. The aim of this single-arm phase II clinical study was to assess ...
BeOne Medicines’ latest clinical update centers on a Phase 1b study titled “A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results